{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-011465","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.302103+00:00","generated_at":"2026-05-31T11:04:36.492512+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Scholar Rock Q2 net loss $0.60/shr; cash $190.5M; Phase 3 SAPPHIRE data on track Q4 2024","bullets":["Net loss $58.5M ($0.60/shr) vs $37.9M ($0.47/shr) in Q2 2023; no revenue.","Cash $190.5M; expected to fund operations into H2 2025.","Phase 3 SAPPHIRE topline data for apitegromab in SMA expected Q4 2024; commercial launch targeted 2025 if successful.","Phase 2 EMBRAZE (apitegromab + GLP-1 in obesity) now expects topline data Q2 2025; IND for SRK-439 planned in 2025.","Long-term TOPAZ data: 48-month mean HFMSE improvement 5.3 points (2-21 yrs); >90% patient retention."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-011465","json":"https://secwatch.observer/filing/0001558370-24-011465.json","markdown":"https://secwatch.observer/filing/0001558370-24-011465.md","text":"https://secwatch.observer/filing/0001558370-24-011465.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000155837024011465/0001558370-24-011465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000155837024011465/srrk-20240808x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:04:36.492512+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}